Researchers at MIT and elsewhere have developed Boltz-2, an open-source generative AI model that can help researchers find new medicines faster, reports Alex Knapp for Forbes. The tool “can not only predict the structure of proteins, it can also predict its binding affinity–that is, how well a potential drug is able to interact with that protein,” explains Knapp. “This is crucial in the early stages of developing a new medicine.”
Wall Street Journal reporter Dominique Mosbergen spotlights how Prof. James Collins and his lab have built their “own algorithms to trawl chemical databases, such as those of existing pharmaceutical drugs, for potential antibacterial compounds.” Collins’ His lab is “also experimenting with using generative AI to design completely new molecules that could kill bacteria,” writes Mosbergen.
Researchers from MIT and other institutions have uncovered new pathways, along with identifying genes, that may contribute to the development of a new class of drugs to treat Alzheimer’s disease, reports John R. Ellement for The Boston Globe. “The drugs currently approved to treat Alzheimer’s have not been as successful as hoped,” Ellement explains. “Those drugs tend to target amyloid plaques in the brain, but the new research suggests other areas to target.”
Emily Young '18, co-founder and CEO of MIT D-Lab spinout Moving Health, speaks with The World’s Jeremy Siegel about her startup’s commitment to transforming “maternal healthcare in rural Ghana, where access to ambulances is severely limited, by creating an emergency transportation network that uses motorized ambulances." Young discovered that “what rural communities needed most was transportation that could actually handle rough terrain while still being cost effective and easy to scale at a local level.”
Prof. Canan Dagdeviren speaks with NBC Boston reporter Priscilla Casper about her work developing a wearable ultrasound scanner that can be used for early breast cancer detection, with the goal of empowering “women to monitor their own bodies, on their own time and in the comfort of their own home.” Dagdeviren explains that “our hope [is to] collect a lot of data and use AI to predict what will happen to breast tissue over time.”
The new Hood Pediatric Innovation Hub, a cornerstone of MIT’s Health and Life Sciences Collaborative (MIT HEALS), is aimed at addressing “underinvestment in pediatric healthcare innovations,” reports Isabel Hart for the Boston Business Journal. Prof. Elazer Edelman, faculty lead for the hub, explains that: “We are trying to build a new culture providing innovation to those who have least access to it and will most benefit from it.”
Syntis Bio, a biopharmaceutical company co-founded by Prof. Giovanni Traverso and Prof. Robert Langer, is developing a daily obesity pill that mimics the effects of gastric bypass, reports Emily Mullin for Wired. “This material is something you would take as a capsule or liquid, but the next day it's gone because of the natural turnover of our mucosal surface in the GI tract,” says Traverso.
“AT MIT innovation ranges from awe-inspiring technology to down-to-earth creativity,” notes Chronicle during a visit to campus to peek behind the scenes at the innovations underway at the Institute. Classes taught by Prof. Erik Demaine are a “mix of rigorous math and creative collaboration,” host Anthony Everett explains, highlighting how Demaine’s work in computational origami has found its way into practical applications in such fields as medicine, architecture and space exploration. “I think origami provides a really powerful tool for making transformable shapes,” Demaine relates.
Chronicle visits MIT to learn more about how the Institute “nurtures groundbreaking efforts, reminding us that creativity and science thrive together, inspiring future advancements in engineering, medicine, and beyond.” Prof. Julien de Wit and Research Scientist Artem Burdanov discuss their planetary defense efforts aimed at identifying small asteroids that could pose a threat to Earth, and Prof. Canan Dağdeviren demonstrates her work developing ultrasound devices to detect the earliest stages of breast cancer. Host Anthony Everett notes that: “Big ideas have a way of breaking out of conventional boundaries, just part of what makes MIT one giant laboratory of groundbreaking ideas."
MIT researchers have developed “self-injectable contraceptive shots that work similarly to contraceptive implants,” reports Margherita Bassi for Gizmodo. “The shots would result in a highly effective and long-term contraceptive method more accessible to women who lack easy access to medical infrastructure,” explains Bassi. “Additionally, the design could be used to administer other long-term medications, such as those for HIV.”
MIT researchers have developed a “simple way to administer long-acting drug delivery systems without the need for invasive procedures – an appealing prospect for parts of the world with poor medical infrastructure,” reports Nicola Davis for The Guardian. “It’s suitable for any poorly soluble hydrophobic drug, especially where long-acting delivery is needed,” says Prof. Giovanni Traverso, “This includes treatments for HIV, TB, schizophrenia, chronic pain, or metabolic disease.”
Prof. Jeffrey Harris speaks with Newsweek reporter Jasmine Laws about how a recession could impact Medicare. "A recession could impact many critical decisions of federal lawmakers, private insurers, healthcare providers, and patients,” says Harris. “The U.S. Congress may decide to let stand the Medicare physician payment cut that became effective on January 1 of this year. Reduced physician payments under conventional Medicare may cause doctors, hospitals and other providers to shift their resources toward the care of younger, commercially insured patients."
Researchers from MIT have “identified genes that the tuberculous bacteria rely on to survive and spread,” reports Allison DeAngelis for STAT. “Until now, very little was known about how tuberculous bacteria survived temperature changes, oxygen levels, humidity, and other environmental factors during the journey from one person’s lungs to another’s,” explains DeAngelis.
Writing for The Boston Globe, Prof. Pierre Azoulay and Prof. Jeffrey Flier of Harvard Medical School make the case that any reforms at the NIH “should be grounded in evidence rather than tradition, avoiding the influence of special interests or political considerations.” They add that this approach “is an acknowledgement of NIH’s accomplishments and a charge to adapt it to the new realities of 21st-century science. The overarching goal must be to secure and enhance the decades-long role of the United States at the forefront of biomedical research, an outcome that the public both wants and deserves.”
MIT has multiple projects represented in this year’s STAT Madness, a bracket-style competition “highlighting important scientific advances emerging from labs at the nation’s universities, medical schools, and other U.S. research institutions and companies,” reports STAT staff.